RU2013146619A - Производные пиридопиразина и их применение - Google Patents
Производные пиридопиразина и их применение Download PDFInfo
- Publication number
- RU2013146619A RU2013146619A RU2013146619/15A RU2013146619A RU2013146619A RU 2013146619 A RU2013146619 A RU 2013146619A RU 2013146619/15 A RU2013146619/15 A RU 2013146619/15A RU 2013146619 A RU2013146619 A RU 2013146619A RU 2013146619 A RU2013146619 A RU 2013146619A
- Authority
- RU
- Russia
- Prior art keywords
- pyrazin
- pyrido
- phenylbutyl
- urea
- alkyl
- Prior art date
Links
- BQJCIWPXUFAVBN-UHFFFAOYSA-N CC(CCCc1ccccc1)NC(Nc(cc1)nc2c1ncc(-c1ccncc1)n2)=O Chemical compound CC(CCCc1ccccc1)NC(Nc(cc1)nc2c1ncc(-c1ccncc1)n2)=O BQJCIWPXUFAVBN-UHFFFAOYSA-N 0.000 description 1
- ZUVOFQNVBLWJHN-UHFFFAOYSA-N COc1cc(Nc2cnc(ccc(NC(NCCCCc3ccccc3)=O)n3)c3n2)cc(O)c1OC Chemical compound COc1cc(Nc2cnc(ccc(NC(NCCCCc3ccccc3)=O)n3)c3n2)cc(O)c1OC ZUVOFQNVBLWJHN-UHFFFAOYSA-N 0.000 description 1
- JCXBSFZMBCBDAC-UHFFFAOYSA-N O=C(NCCCCc1ccccc1)Nc(cc1)nc2c1ncc(-c1c[n](CCN3CCOCC3)nc1)n2 Chemical compound O=C(NCCCCc1ccccc1)Nc(cc1)nc2c1ncc(-c1c[n](CCN3CCOCC3)nc1)n2 JCXBSFZMBCBDAC-UHFFFAOYSA-N 0.000 description 1
- PROTVEWOFXXQRV-UHFFFAOYSA-N O=C(NCCCCc1ccccc1)Nc(cc1)nc2c1ncc(-c1ccn[nH]1)n2 Chemical compound O=C(NCCCCc1ccccc1)Nc(cc1)nc2c1ncc(-c1ccn[nH]1)n2 PROTVEWOFXXQRV-UHFFFAOYSA-N 0.000 description 1
- WDZIFPGUPLYIOC-UHFFFAOYSA-N O=C(NCCCCc1ccccc1)Nc1ccc2ncc(N3CCOCC3)nc2n1 Chemical compound O=C(NCCCCc1ccccc1)Nc1ccc2ncc(N3CCOCC3)nc2n1 WDZIFPGUPLYIOC-UHFFFAOYSA-N 0.000 description 1
- FNRZJZHDLZAOOT-UHFFFAOYSA-N OCc1cc(-c2nc(nc(cc3)NC(NCCCCc4ccccc4)=O)c3nc2)ccc1 Chemical compound OCc1cc(-c2nc(nc(cc3)NC(NCCCCc4ccccc4)=O)c3nc2)ccc1 FNRZJZHDLZAOOT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472245P | 2011-04-06 | 2011-04-06 | |
| EP11161248.7 | 2011-04-06 | ||
| US61/472,245 | 2011-04-06 | ||
| EP11161248A EP2508184A1 (fr) | 2011-04-06 | 2011-04-06 | Dérivés de pyridopyrazine et leur utilisation |
| PCT/EP2012/056138 WO2012136691A1 (fr) | 2011-04-06 | 2012-04-04 | Dérivés de pyridopyrazine et leur utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013146619A true RU2013146619A (ru) | 2015-05-20 |
Family
ID=44350566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013146618/04A RU2013146618A (ru) | 2011-04-06 | 2012-04-04 | Производные пиридопиразина и их применение |
| RU2013146619/15A RU2013146619A (ru) | 2011-04-06 | 2012-04-04 | Производные пиридопиразина и их применение |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013146618/04A RU2013146618A (ru) | 2011-04-06 | 2012-04-04 | Производные пиридопиразина и их применение |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8912189B2 (fr) |
| EP (3) | EP2508184A1 (fr) |
| JP (2) | JP5963844B2 (fr) |
| KR (2) | KR20140025443A (fr) |
| CN (2) | CN103826636A (fr) |
| AR (2) | AR085844A1 (fr) |
| AU (2) | AU2012238678B2 (fr) |
| BR (1) | BR112013025630A2 (fr) |
| CA (2) | CA2832321A1 (fr) |
| ES (1) | ES2552515T3 (fr) |
| IL (2) | IL228436A0 (fr) |
| MX (2) | MX2013011490A (fr) |
| NZ (1) | NZ615578A (fr) |
| PL (1) | PL2694067T3 (fr) |
| RU (2) | RU2013146618A (fr) |
| SG (2) | SG193978A1 (fr) |
| TW (2) | TWI564299B (fr) |
| WO (2) | WO2012136691A1 (fr) |
| ZA (2) | ZA201306862B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| US20170168056A1 (en) * | 2015-11-13 | 2017-06-15 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating cancer cells |
| BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
| WO2017180817A1 (fr) * | 2016-04-15 | 2017-10-19 | Musc Foundation For Research Development | Traitement de la septicémie et du sdra à l'aide d'inhibiteurs d'erk |
| KR20200041294A (ko) | 2017-06-21 | 2020-04-21 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| EP3641794A4 (fr) * | 2017-06-23 | 2021-03-24 | The Trustees of Columbia University in the City of New York | Procédés de prévention et de traitement de maladies caractérisées par un dysfonctionnement synaptique et une neurodégénérescence, y compris la maladie d'alzheimer |
| US20210238605A1 (en) * | 2018-06-15 | 2021-08-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity |
| CN112830897B (zh) * | 2019-11-22 | 2022-09-09 | 石家庄以岭药业股份有限公司 | 含脲基苯并咪唑类衍生物及其制备方法和应用 |
| EP4271675A1 (fr) * | 2020-12-31 | 2023-11-08 | Evrys Bio, LLC | Compositions antitumorales et méthodes |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3809695A (en) | 1967-04-19 | 1974-05-07 | Degussa | 2,6-dichloro-3-nitro-pyridine |
| KR100369275B1 (ko) | 1995-03-28 | 2003-05-09 | 스미또모 가가꾸 고오교오 가부시끼가이샤 | 아미노니트로피리딘류의제조방법 |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| JP4403482B2 (ja) | 1997-12-22 | 2010-01-27 | バイエル コーポレイション | 置換複素環尿素合成のための中間体およびその製造方法 |
| CN101851173A (zh) | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
| WO2003068223A1 (fr) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Urees aryliques a kinase de raf et activite inhibitrice d'angiogenese |
| JP4451136B2 (ja) | 2002-04-08 | 2010-04-14 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性阻害薬 |
| AU2003226301A1 (en) | 2002-04-08 | 2003-10-20 | Merck And Co., Inc. | Method of treating cancer |
| US7223738B2 (en) | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US7718651B2 (en) | 2002-07-02 | 2010-05-18 | Southern Research Institute | Inhibitors of FtsZ and uses thereof |
| DE502004008322D1 (de) | 2003-05-23 | 2008-12-04 | Aterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
| DE10323345A1 (de) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| WO2005007099A2 (fr) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Inhibiteurs de la pkb utilises comme agents antitumoraux |
| AU2004297235A1 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| GB0413953D0 (en) | 2004-06-22 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| EP1790342A1 (fr) * | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal |
| AU2006313701B2 (en) | 2005-11-11 | 2012-05-31 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1785423A1 (fr) * | 2005-11-11 | 2007-05-16 | Zentaris GmbH | Pyridopyrazines et leur utilisation en tant que modulateurs de kinases |
| US7733554B2 (en) * | 2006-03-08 | 2010-06-08 | E Ink Corporation | Electro-optic displays, and materials and methods for production thereof |
| KR101097177B1 (ko) | 2006-07-06 | 2011-12-22 | 한국화학연구원 | 2-알킬레닐옥시-3-에티닐피리도［2,3-ｂ］피라진 유도체 |
| GB0614471D0 (en) | 2006-07-20 | 2006-08-30 | Syngenta Ltd | Herbicidal Compounds |
| US20100093738A1 (en) | 2006-10-06 | 2010-04-15 | Basf Se | Fungicidal Compounds and Fungicidal Compositions |
| EP1990342A1 (fr) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Dérivés de pyridopyrazine, processus de fabrication et utilisations correspondantes |
| WO2009073513A1 (fr) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Biomarqueurs braf |
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
-
2011
- 2011-04-06 EP EP11161248A patent/EP2508184A1/fr not_active Withdrawn
-
2012
- 2012-04-03 TW TW101111889A patent/TWI564299B/zh not_active IP Right Cessation
- 2012-04-03 TW TW101111888A patent/TW201302742A/zh unknown
- 2012-04-04 RU RU2013146618/04A patent/RU2013146618A/ru not_active Application Discontinuation
- 2012-04-04 BR BR112013025630A patent/BR112013025630A2/pt not_active IP Right Cessation
- 2012-04-04 KR KR1020137029386A patent/KR20140025443A/ko not_active Application Discontinuation
- 2012-04-04 WO PCT/EP2012/056138 patent/WO2012136691A1/fr active Application Filing
- 2012-04-04 SG SG2013072624A patent/SG193978A1/en unknown
- 2012-04-04 JP JP2014503125A patent/JP5963844B2/ja not_active Expired - Fee Related
- 2012-04-04 JP JP2014503127A patent/JP2014510125A/ja active Pending
- 2012-04-04 US US13/439,107 patent/US8912189B2/en not_active Expired - Fee Related
- 2012-04-04 US US13/439,150 patent/US8791118B2/en not_active Expired - Fee Related
- 2012-04-04 EP EP12713706.5A patent/EP2694068A1/fr not_active Withdrawn
- 2012-04-04 CA CA2832321A patent/CA2832321A1/fr not_active Abandoned
- 2012-04-04 NZ NZ615578A patent/NZ615578A/en not_active IP Right Cessation
- 2012-04-04 AU AU2012238678A patent/AU2012238678B2/en not_active Ceased
- 2012-04-04 CN CN201280019613.9A patent/CN103826636A/zh active Pending
- 2012-04-04 MX MX2013011490A patent/MX2013011490A/es unknown
- 2012-04-04 KR KR1020137029385A patent/KR20140025442A/ko not_active Application Discontinuation
- 2012-04-04 ES ES12713705.7T patent/ES2552515T3/es active Active
- 2012-04-04 CA CA2832337A patent/CA2832337A1/fr not_active Abandoned
- 2012-04-04 MX MX2013011444A patent/MX2013011444A/es unknown
- 2012-04-04 WO PCT/EP2012/056142 patent/WO2012136694A1/fr active Application Filing
- 2012-04-04 AR ARP120101163A patent/AR085844A1/es unknown
- 2012-04-04 AR ARP120101162A patent/AR085843A1/es unknown
- 2012-04-04 SG SG2013074430A patent/SG194097A1/en unknown
- 2012-04-04 EP EP12713705.7A patent/EP2694067B1/fr active Active
- 2012-04-04 PL PL12713705T patent/PL2694067T3/pl unknown
- 2012-04-04 RU RU2013146619/15A patent/RU2013146619A/ru not_active Application Discontinuation
- 2012-04-04 CN CN201280022158.8A patent/CN103501788A/zh active Pending
- 2012-04-04 AU AU2012238681A patent/AU2012238681A1/en not_active Abandoned
-
2013
- 2013-09-12 ZA ZA2013/06862A patent/ZA201306862B/en unknown
- 2013-09-12 ZA ZA2013/06864A patent/ZA201306864B/en unknown
- 2013-09-15 IL IL228436A patent/IL228436A0/en unknown
- 2013-09-15 IL IL228433A patent/IL228433A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013146619A (ru) | Производные пиридопиразина и их применение | |
| JP6586104B2 (ja) | ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法 | |
| JP2014510124A5 (fr) | ||
| JP3544675B2 (ja) | 血管形成阻害活性を有するフタラジン | |
| US7323474B2 (en) | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | |
| JP5826261B2 (ja) | 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン | |
| AU2017258193A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| CN101365454A (zh) | 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物 | |
| CN103102342B (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
| CN102596932A (zh) | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 | |
| CN102413831A (zh) | 取代的咪唑并喹喔啉 | |
| CN102762557A (zh) | 三唑并吡啶 | |
| JP2009535300A (ja) | キナーゼ阻害剤としての新規なシクロブチル化合物 | |
| KR20200027543A (ko) | 섬유증의 치료를 위한 신규의 화합물 및 그의 약학 조성물 | |
| CN105073715B (zh) | 二氢哒嗪‑3,5‑二酮衍生物 | |
| JP2018522886A (ja) | ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール | |
| JP2013530192A (ja) | キナーゼ誘発疾患の処置に有用なビピリジル誘導体 | |
| TW202133844A (zh) | 吖丁啶lpa1受體拮抗劑與抗纖維化藥劑之組合 | |
| JP2016512547A (ja) | 線維症疾患の治療のための化合物 | |
| JP2013520407A (ja) | Ｎａｄｐｈオキシダーゼ阻害剤としてのピラゾロピペリジン誘導体 | |
| CN107108554A (zh) | 作为midh1抑制剂用于治疗肿瘤的1‑环己基‑2‑苯基氨基苯并咪唑 | |
| JP6104824B2 (ja) | ピリド［２，３−ｂ］ピラジン誘導体およびそれらの治療的使用 | |
| CN103582632A (zh) | 取代的苯并咪唑 | |
| TW202104212A (zh) | 以雜環化合物作為激酶抑制劑的治療用途 | |
| RU2404776C2 (ru) | ПРИМЕНЕНИЕ ПИРИМИДИЛАМИНОБЕНЗАМИДОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ЧУВСТВИТЕЛЬНЫХ К МОДУЛЯЦИИ АКТИВНОСТИ КИНАЗЫ Тie-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20180226 |